The success of copyright’s blockbuster initially sparked a surge for major pharmaceutical companies, but recent shifts present a uncertain outlook for shareholders. Lower-cost versions are reducing earnings, and https://lewyswnhq775529.blogdemls.com/40969978/the-blue-pill-and-the-pharmaceutical-industry-a-precarious-bet